231 related articles for article (PubMed ID: 3327377)
21. Reconsideration of contemporary U.S. drug policy.
Solano PL
J Ment Health Policy Econ; 2002 Dec; 5(4):175-83. PubMed ID: 14578551
[TBL] [Abstract][Full Text] [Related]
22. The analysis of policy: understanding the process of policy development.
Ryder D
Addiction; 1996 Sep; 91(9):1265-70. PubMed ID: 8854357
[TBL] [Abstract][Full Text] [Related]
23. Commentary in response to Paulozzi et al.: prescription drug abuse and safe pain management.
Fishman SM
Pharmacoepidemiol Drug Saf; 2006 Sep; 15(9):628-31. PubMed ID: 16862601
[No Abstract] [Full Text] [Related]
24. Resting assured: risk management in the prescription of controlled substances.
Longo LP
WMJ; 1999; 98(1):23-9. PubMed ID: 10050150
[No Abstract] [Full Text] [Related]
25. New York State's Triplicate Prescription Program.
Eadie JL
NIDA Res Monogr; 1993; 131():176-93. PubMed ID: 8413528
[No Abstract] [Full Text] [Related]
26. Guiding principles of international and federal laws pertaining to medical use and diversion of controlled substances.
Joranson DE
NIDA Res Monogr; 1993; 131():18-34. PubMed ID: 8413529
[No Abstract] [Full Text] [Related]
27. Public policy statement on persons with alcohol and other drug (AOD) problems and the criminal justice system. American Society of Addiction Medicine.
J Addict Dis; 1994; 13(4):234-7. PubMed ID: 7734472
[No Abstract] [Full Text] [Related]
28. Prescription drug diversion: "what Lola wants, Lola gets".
Thomison JB
J Tenn Med Assoc; 1989 Jan; 82(1):35-7. PubMed ID: 2927111
[No Abstract] [Full Text] [Related]
29. Dangers of self-prescribing and prescribing for family members.
Price M; McIntyre BW
Med Health R I; 2007 Jun; 90(6):178-81. PubMed ID: 17633590
[No Abstract] [Full Text] [Related]
30. Va. doctors to report controlled substances. Program targets drugs with high potential for abuse, e.g., oxycontin, percocet.
Lubell J
Mod Healthc; 2006 Jun; 36(26):32. PubMed ID: 16841650
[No Abstract] [Full Text] [Related]
31. Drug use and abuse in five US communities.
Weissman MM; Johnson J
N Y State J Med; 1991 Nov; 91(11 Suppl):19S-23S. PubMed ID: 1771054
[TBL] [Abstract][Full Text] [Related]
32. Formulation considerations for the development of medications with abuse potential.
Mansbach RS; Moore RA
Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S15-22. PubMed ID: 16472940
[TBL] [Abstract][Full Text] [Related]
33. Multidisciplinary committee on the abuse of prescription medications.
Britton ML; Lobeck FG; Kelly MW
Am J Hosp Pharm; 1994 Jan; 51(1):85-8. PubMed ID: 8135265
[TBL] [Abstract][Full Text] [Related]
34. Prescription drug use and abuse.
Meadows M
FDA Consum; 2001; 35(5):18-24. PubMed ID: 11697087
[No Abstract] [Full Text] [Related]
35. The challenges in developing a rational cannabis policy.
Hall W; Lynskey M
Curr Opin Psychiatry; 2009 May; 22(3):258-62. PubMed ID: 19293714
[TBL] [Abstract][Full Text] [Related]
36. The costs of compliance.
Leeman E
J Am Acad Psychoanal Dyn Psychiatry; 2007; 35(2):179-87. PubMed ID: 17650971
[TBL] [Abstract][Full Text] [Related]
37. Drug & alcohol testing. Is your corporate culture on drugs?
Nadell BJ
Occup Health Saf; 2001 Aug; 70(8):28-31, 75. PubMed ID: 11523282
[No Abstract] [Full Text] [Related]
38. Fifteen solutions to the problems of prescription drug abuse.
Lurie P; Lee PR
J Psychoactive Drugs; 1991; 23(4):349-57. PubMed ID: 1813607
[TBL] [Abstract][Full Text] [Related]
39. Case history: dangers of self-prescription.
Johnston GP
J Indiana State Med Assoc; 1979 Aug; 72(8):570-2. PubMed ID: 512400
[No Abstract] [Full Text] [Related]
40. Excessive dispensing of controlled substances: a legal perspective.
Morgan WR
Ala Med; 1985 Feb; 54(8):13-7. PubMed ID: 3976450
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
